Trevena (NASDAQ:TRVN) Shares Cross Above 50 Day Moving Average – What’s Next?

Trevena, Inc. (NASDAQ:TRVN)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.80 and traded as high as $1.83. Trevena shares last traded at $1.76, with a volume of 6,213 shares.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TRVN. HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th. StockNews.com initiated coverage on Trevena in a research note on Saturday. They set a “sell” rating for the company.

Trevena Stock Down 1.4 %

The firm has a market cap of $1.52 million, a P/E ratio of -0.04 and a beta of 1.08. The business’s 50 day moving average is $1.80 and its 200-day moving average is $4.15.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million for the quarter. As a group, equities analysts predict that Trevena, Inc. will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.